Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older
Latest Information Update: 03 Mar 2023
At a glance
- Drugs Norovirus vaccine quadrivalent-Anhui Zhifei Longcom Biologic Pharmacy (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
- 28 Feb 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 28 Feb 2023 Planned primary completion date changed from 2 Feb 2023 to 2 Feb 2024.
- 28 Feb 2023 Status changed from recruiting to active, no longer recruiting.